Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Bo Arve"'
Autor:
Renée Procopio-Melino, Frank W. Kotch, Amar S. Prashad, Jose M. Gomes, Wenge Wang, Bo Arve, Andrew Dawdy, Lawrence Chen, Justin Sperry, Christine Hosselet, Tao He, Ronald Kriz, Laura Lin, Kimberly Marquette, Lioudmila Tchistiakova, Will Somers, Jason C. Rouse, Xiaotian Zhong
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Next-generation site-specific cysteine-based antibody–drug-conjugates (ADCs) broaden therapeutic index by precise drug-antibody attachments. However, manufacturing such ADCs for clinical validation requires complex full reduction and reoxi
Externí odkaz:
https://doaj.org/article/5cda877d16ac4d3e838e8490f8f4c4f8
Autor:
Verl Sriskanda, Amar S. Prashad, Ivette Carino, Janine De Leon, Brenda Carrillo Conde, Seyed Pouria Motevalian, Bo Arve, Jonathan Steen
Publikováno v:
Biotechnology Progress. 37
Over the past decade, single-use tangential flow filtration (TFF) technologies have emerged to reduce system preparation time, promote fast and flexible product change over, and ultimately shorten process development and manufacturing time/cost. In t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9acc6eb121bd8f8f80f133dce3c6f7b3
https://doi.org/10.1002/btpr.3204
https://doi.org/10.1002/btpr.3204
Publikováno v:
Organic Process Research & Development. 21:601-610
As antibody drug conjugates (ADCs) move through clinical development, from phase 1 to pivotal studies, supported by clinical efficacy and appropriate safety, the development of late stage and commercial-ready processes and methods becomes a priority.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::569c164ce1514a49d79015e81bb92b54
https://doi.org/10.1021/acs.oprd.7b00023
https://doi.org/10.1021/acs.oprd.7b00023
Autor:
April Xu, Bo Arve, Leo Joseph Letendre, Amar S. Prashad, Patel Vimalkumar Babubhai, Birte Nolting
Publikováno v:
Organic Process Research & Development. 21:590-600
In the development of new antibody drug conjugates (ADCs), the activities performed by discovery groups typically focus on the rapid and comprehensive screening of many conjugates to find the ones with the desired efficacy and safety profiles. These
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c85389f5034a95f017f206f07ff9faa
https://doi.org/10.1021/acs.oprd.7b00020
https://doi.org/10.1021/acs.oprd.7b00020
Autor:
Amy Tam, Aaron M. D’Antona, Tao He, Yen-Tung Luan, Laura Lin, Wenge Wang, Darren Ferguson, Xiaotian Zhong, Lioudmila Tchistiakova, Eric Sousa, Scott Gatto, Amar S. Prashad, Ronald Kriz, Weijun Ma, Jing Zhou, Bo Arve, William S. Somers, Justin Cohen, Richard Zollner
Publikováno v:
Journal of biotechnology. 248
Protein modifications by intricate cellular machineries often redesign the structure and function of existing proteins to impact biological networks. Disulfide bond formation between cysteine (Cys) pairs is one of the most common modifications found
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::457002961c0ca7824988d539bf84331d
https://pubmed.ncbi.nlm.nih.gov/28300660
https://pubmed.ncbi.nlm.nih.gov/28300660